Prediction of Maternal and Fetal Pharmacokinetics of Dolutegravir and Raltegravir Using Physiologically Based Pharmacokinetic Modeling

No abstract is available for this paper.

• Publication year

  2020

• Venue

  Clinical Pharmacokinetics

• Publication date

  2020-05-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s40262-020-00897-9PMID 32451908PMCID PMC7666002
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Physiologically Based Pharmacokinetic Models to Predict Maternal Pharmacokinetics and Fetal Exposure to Emtricitabine and Acyclovir

  2020cited by this paper
• Impact of gastrointestinal physiology on drug absorption in special populations - An UNGAP review.

  2020cited by this paper
• The Effect of Pregnancy on the Pharmacokinetics of Total and Unbound Dolutegravir and Its Main Metabolite in Women Living With Human Immunodeficiency Virus.

  2020cited by this paper
• Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States

  2020cited by this paper
• Drug Transporters Expressed in the Human Placenta and Models for Studying Maternal‐Fetal Drug Transfer

  2019cited by this paper
• Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study)

  2019cited by this paper
• Physiologically Based Pharmacokinetic Modeling to Characterize Acetaminophen Pharmacokinetics and N-Acetyl-p-Benzoquinone Imine (NAPQI) Formation in Non-Pregnant and Pregnant Women

  2019cited by this paper
• Clinical Extrapolation of the Effects of Dolutegravir and Other HIV Integrase Inhibitors on Folate Transport Pathways

  2019cited by this paper
• Pharmacokinetics of dolutegravir 100 mg once daily with rifampicin.

  2019cited by this paper
• Physiologically Based Pharmacokinetic Modeling in Pregnancy: A Systematic Review of Published Models

  2018cited by this paper
• A Physiologically Based Pharmacokinetic Model for Pregnant Women to Predict the Pharmacokinetics of Drugs Metabolized Via Several Enzymatic Pathways

  2018cited by this paper
• Applied Concepts in PBPK Modeling: How to Extend an Open Systems Pharmacology Model to the Special Population of Pregnant Women

  2018cited by this paper
• Reconsidering the Number of Women With HIV Infection Who Give Birth Annually in the United States

  2018cited by this paper
• Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV

  2018cited by this paper
• Physiologically Based Pharmacokinetic Modeling of Renally Cleared Drugs in Pregnant Women

  2017cited by this paper
• Gastrointestinal Hormone Cholecystokinin Increases P-Glycoprotein Membrane Localization and Transport Activity in Caco-2 Cells.

  2017cited by this paper
• Prediction of Fetal Darunavir Exposure by Integrating Human Ex-Vivo Placental Transfer and Physiologically Based Pharmacokinetic Modeling

  2017cited by this paper
• Development of a Novel Maternal-Fetal Physiologically Based Pharmacokinetic Model II: Verification of the Model for Passive Placental Permeability Drugs

  2017cited by this paper
• Estimated Perinatal HIV Infection Among Infants Born in the United States, 2002-2013

  2017cited by this paper
• Gestation-Specific Changes in the Anatomy and Physiology of Healthy Pregnant Women: An Extended Repository of Model Parameters for Physiologically Based Pharmacokinetic Modeling in Pregnancy

  2017cited by this paper
• An evidence‐based recommendation to increase the dosing frequency of buprenorphine during pregnancy

  2017cited by this paper
• Placental transfer of the HIV integrase inhibitor dolutegravir in an ex vivo human cotyledon perfusion model.

  2016cited by this paper
• Atazanavir increases the plasma concentrations of 1200 mg raltegravir dose

  2016cited by this paper
• Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation

  2016cited by this paper
• Integrase inhibitors in late pregnancy and rapid HIV viral load reduction.

  2016cited by this paper
• Prediction of human fetal pharmacokinetics using ex vivo human placenta perfusion studies and physiologically based models.

  2016cited by this paper
• Evaluation of the impact of multivalent metal ions on the permeation behavior of Dolutegravir sodium

  2016cited by this paper
• Pharmacokinetics of Raltegravir in HIV-Infected Patients on Rifampicin-Based Antitubercular Therapy.

  2015cited by this paper
• Quantitative structure-activity relationship model for the fetal-maternal blood concentration ratio of chemicals in humans.

  2015cited by this paper
• The effect of maternal obesity on the expression and functionality of placental P-glycoprotein: Implications in the individualized transplacental digoxin treatment for fetal heart failure.

  2015cited by this paper
• Raltegravir in HIV-1-Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy.

  2015cited by this paper
• Ultrasonographic evaluation of gastric content during labour under epidural analgesia: a prospective cohort study.

  2014cited by this paper
• Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir

  2014cited by this paper
• Raltegravir Pharmacokinetics During Pregnancy

  2014cited by this paper
• Placental profiling of UGT1A enzyme expression and activity and interactions with preeclampsia at term

  2014cited by this paper
• A Pharmacokinetic Comparison of Adult and Paediatric Formulations of Raltegravir in Healthy Adults

  2014cited by this paper
• In Vitro Investigations into the Roles of Drug Transporters and Metabolizing Enzymes in the Disposition and Drug Interactions of Dolutegravir, a HIV Integrase Inhibitor

  2013cited by this paper
• Lack of Pharmacokinetic Interaction between Rilpivirine and Integrase Inhibitors Dolutegravir and GSK1265744

  2013cited by this paper
• Predicting intestinal absorption of raltegravir using a population-based ADME simulation.

  2013cited by this paper
• Pharmacokinetics of Single-Dose Dolutegravir in HIV-Seronegative Subjects With Moderate Hepatic Impairment Compared to Healthy Matched Controls

  2013cited by this paper
• Metabolism, Excretion, and Mass Balance of the HIV-1 Integrase Inhibitor Dolutegravir in Humans

  2013cited by this paper
• Safety, Tolerability, and Pharmacokinetics of the HIV Integrase Inhibitor Dolutegravir Given Twice Daily With Rifampin or Once Daily With Rifabutin: Results of a Phase 1 Study Among Healthy Subjects

  2013cited by this paper
• Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment

  2013cited by this paper
• Divalent Metals and pH Alter Raltegravir Disposition In Vitro

  2012cited by this paper
• A Framework for Elimination of Perinatal Transmission of HIV in the United States

  2012cited by this paper
• Effect of Food on the Pharmacokinetics of the Integrase Inhibitor Dolutegravir

  2011cited by this paper
• PaDEL‐descriptor: An open source software to calculate molecular descriptors and fingerprints

  2011cited by this paper
• Effect of Low‐, Moderate‐, and High‐Fat Meals on Raltegravir Pharmacokinetics

  2011influential reference
• Raltegravir Is a Substrate for SLC22A6: a Putative Mechanism for the Interaction between Raltegravir and Tenofovir

  2010cited by this paper
• Effects of omeprazole on plasma levels of raltegravir.

  2009cited by this paper
• Quantitative Prediction of Human Clearance Guiding the Development of Raltegravir (MK-0518, Isentress) and Related HIV Integrase Inhibitors

  2009cited by this paper
• Effect of Rifampin, a Potent Inducer of Drug-Metabolizing Enzymes, on the Pharmacokinetics of Raltegravir

  2009cited by this paper
• Pharmacokinetics and Safety of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor, in Healthy Volunteers

  2009cited by this paper
• Minimal Effects of Ritonavir and Efavirenz on the Pharmacokinetics of Raltegravir

  2008cited by this paper
• Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination

  2008cited by this paper
• Cyclooxygenase Inhibitors Down Regulate P-glycoprotein in Human Colorectal Caco-2 Cell Line

  2008cited by this paper
• Safety, Tolerability, and Pharmacokinetics of Raltegravir After Single and Multiple Doses in Healthy Subjects

  2008cited by this paper
• Metabolism and Disposition in Humans of Raltegravir (MK-0518), an Anti-AIDS Drug Targeting the Human Immunodeficiency Virus 1 Integrase Enzyme

  2007cited by this paper
• Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions.

  2006cited by this paper
• Expression of the multidrug resistance P-glycoprotein, (ABCB1 glycoprotein) in the human placenta decreases with advancing gestation.

  2006cited by this paper
• Antiretroviral Activity, Pharmacokinetics, and Tolerability of MK-0518, a Novel Inhibitor of HIV-1 Integrase, Dosed As Monotherapy for 10 Days in Treatment-Naive HIV-1-Infected Individuals

  2006cited by this paper
• Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases.

  2005cited by this paper
• Gene Expression Profiles of ABC Transporters and Cytochrome P450 3A in Caco-2 and Human Colorectal Cancer Cell Lines

  2003cited by this paper
• Gene expression of CYP3A4, ABC‐transporters (MDR1 and MRP1‐MRP5) and hPXR in three different human colon carcinoma cell lines

  2003cited by this paper
• Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR.

  2003cited by this paper
• Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution.

  2002influential reference
• Prediction of adipose tissue: plasma partition coefficients for structurally unrelated drugs.

  2001cited by this paper
• CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 020951 CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW(S)

  1998cited by this paper
• An evaluation of gastric emptying times in pregnancy and the puerperium

  1993cited by this paper
• The Significance of Plasma Protein Binding on the Fetal/Maternal Distribution of Drugs at Steady-State

  1988cited by this paper
• Drug-binding properties of human α-foetoprotein

  1985cited by this paper
• Drug-binding properties of human alpha-foetoprotein.

  1985cited by this paper
• Drug-binding properties of rat alpha 1-foetoprotein. Binding of warfarin, phenylbutazone, azapropazone, diazepam, digitoxin and cholic acid.

  1984cited by this paper
• The prenatal and postnatal development of UDP-glucuronyltransferase activity towards bilirubin and the effect of premature birth on this activity in the human liver.

  1981cited by this paper
• DRUG‐PROTEIN BINDING IN THE NEWBORN INFANT *

  1973cited by this paper
• The binding of sulfaphenazole to fetal, neonatal, and adult human plasma albumin

  1971cited by this paper
• GASTRIC EMPTYING TIME IN LATE PREGNANCY AND LABOUR

  1970cited by this paper

• Strategy advancements in placental pharmacokinetics: from in vitro experiments to in silico prediction

  2025cites this paper
• Safety and Efficacy of Antiviral Drugs and Vaccines in Pregnant Women: Insights from Physiologically Based Pharmacokinetic Modeling and Integration of Viral Infection Dynamics

  2024cites this paper
• Labetalol Dosing in Pregnancy: PBPK/PD and CYP2C19 Polymorphisms

  2024cites this paper
• Challenges, risks, and opportunities of antiretroviral drugs in women of reproductive potential

  2024cites this paper
• Mechanistic Modeling of the Drug‐Drug Interaction Between Efavirenz and Dolutegravir: Is This Interaction Clinically Relevant When Switching From Efavirenz to Dolutegravir During Pregnancy?

  2023cites this paper
• Pregnancy-PBPK models: how are biochemical and physiological processes integrated?

  2023cites this paper
• Use of Medicines in Children: Pharmacological and Practical Issues

  2023cites this paper
• Assessing the contribution of UGT isoforms on raltegravir drug disposition through PBPK modeling.

  2022cites this paper
• Application of Physiologically Based Pharmacokinetic Modeling to Predict Maternal Pharmacokinetics and Fetal Exposure to Oxcarbazepine

  2022cites this paper
• A review of pregnancy-induced changes in opioid pharmacokinetics, placental transfer, and fetal exposure: Towards fetomaternal physiologically-based pharmacokinetic modeling to improve the treatment of neonatal opioid withdrawal syndrome.

  2021cites this paper
• Physiologically Based Pharmacokinetic Modeling Framework to Predict Neonatal Pharmacokinetics of Transplacentally Acquired Emtricitabine, Dolutegravir, and Raltegravir

  2021cites this paper
• When special populations intersect with drug–drug interactions: Application of physiologically‐based pharmacokinetic modeling in pregnant populations

  2021cites this paper
• Regulatory Considerations for the Mother, Fetus and Neonate in Fetal Pharmacology Modeling

  2021cites this paper
• Mechanistic Coupling of a Novel in silico Cotyledon Perfusion Model and a Physiologically Based Pharmacokinetic Model to Predict Fetal Acetaminophen Pharmacokinetics at Delivery

  2021cites this paper
• Mechanistic Modeling of Maternal Lymphoid and Fetal Plasma Antiretroviral Exposure During the Third Trimester

  2021cites this paper
• Characterization of Plasma Protein Alterations in Pregnant and Postpartum Individuals Living With HIV to Support Physiologically-Based Pharmacokinetic Model Development

  2021cites this paper
• Mechanistic Modeling of Placental Drug Transfer in Humans: How Do Differences in Maternal/Fetal Fraction of Unbound Drug and Placental Influx/Efflux Transfer Rates Affect Fetal Pharmacokinetics?

  2021cites this paper
• Maternal-Fetal Pharmacology of Drugs: A Review of Current Status of the Application of Physiologically Based Pharmacokinetic Models

  2021cites this paper
• Integration of physiological changes during the postpartum period into a PBPK framework and prediction of amoxicillin disposition before and shortly after delivery

  2020cites this paper
• The Revolution in Pediatric Drug Development and Drug Use: Therapeutic Orphans No More.

  2020cites this paper